JP2007536243A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536243A5
JP2007536243A5 JP2007511494A JP2007511494A JP2007536243A5 JP 2007536243 A5 JP2007536243 A5 JP 2007536243A5 JP 2007511494 A JP2007511494 A JP 2007511494A JP 2007511494 A JP2007511494 A JP 2007511494A JP 2007536243 A5 JP2007536243 A5 JP 2007536243A5
Authority
JP
Japan
Prior art keywords
group
phospholipase
membered ring
groups
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007511494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536243A (ja
Filing date
Publication date
Priority claimed from US10/838,879 external-priority patent/US20050244367A1/en
Application filed filed Critical
Publication of JP2007536243A publication Critical patent/JP2007536243A/ja
Publication of JP2007536243A5 publication Critical patent/JP2007536243A5/ja
Pending legal-status Critical Current

Links

JP2007511494A 2004-05-03 2005-05-03 ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療 Pending JP2007536243A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/838,879 US20050244367A1 (en) 2004-05-03 2004-05-03 Phospholipase inhibitors localized in the gastrointestinal lumen
PCT/US2005/015281 WO2005112953A2 (en) 2004-05-03 2005-05-03 Treatment of hypercholesterolemia, hypertriglyceridemia and cardiovascular-related conditions using phosphalipase-a2 inhibitors

Publications (2)

Publication Number Publication Date
JP2007536243A JP2007536243A (ja) 2007-12-13
JP2007536243A5 true JP2007536243A5 (cg-RX-API-DMAC7.html) 2008-06-19

Family

ID=35187321

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007511494A Pending JP2007536243A (ja) 2004-05-03 2005-05-03 ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療
JP2007511527A Pending JP2007538009A (ja) 2004-05-03 2005-05-03 インドールおよび関連化合物から成るホスホリパーゼ−a2阻害薬を用いた、食事関連疾患の治療
JP2007511528A Pending JP2007536249A (ja) 2004-05-03 2005-05-03 消化器官管腔集中性ホスホリパーゼ阻害薬

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007511527A Pending JP2007538009A (ja) 2004-05-03 2005-05-03 インドールおよび関連化合物から成るホスホリパーゼ−a2阻害薬を用いた、食事関連疾患の治療
JP2007511528A Pending JP2007536249A (ja) 2004-05-03 2005-05-03 消化器官管腔集中性ホスホリパーゼ阻害薬

Country Status (5)

Country Link
US (3) US20050244367A1 (cg-RX-API-DMAC7.html)
EP (3) EP1750699A4 (cg-RX-API-DMAC7.html)
JP (3) JP2007536243A (cg-RX-API-DMAC7.html)
CA (3) CA2565384A1 (cg-RX-API-DMAC7.html)
WO (3) WO2005112953A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008005661A (es) * 2005-11-03 2008-12-15 Ilypsa Inc Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen.
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
WO2008055148A2 (en) * 2006-10-31 2008-05-08 Wyeth Semi-solid formulations of phospholipase enzyme inhibitors
CL2007003143A1 (es) * 2006-10-31 2008-01-25 Wyeth Corp Composicion farmaceutica que comprende un compuesto derivado de indol y un sistema portador que comprende 10-50% de un primer solubilizante, 5-50% de un segundo solubilizante, 10-30% de un primer diluyente y 1-15% de un segundo diluyente; proceso de prepracion; y forma de dosificacion.
WO2009082491A1 (en) * 2007-12-26 2009-07-02 Alp Life Sciences, Llc Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
EP3187182B1 (en) 2008-09-02 2021-03-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX377553B (es) * 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN107684550B (zh) * 2016-08-03 2020-04-10 徐天宏 糖尿病治疗产品及其制备与应用
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN111386279A (zh) 2017-08-04 2020-07-07 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
JP7735185B2 (ja) 2019-02-07 2025-09-08 アルデリックス, インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (cg-RX-API-DMAC7.html) * 1969-12-27 1971-06-29
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
US4432968A (en) * 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
US5274089A (en) * 1985-10-18 1993-12-28 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5196542A (en) * 1985-10-18 1993-03-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
EP0243449A1 (en) * 1985-10-18 1987-11-04 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5145874A (en) * 1985-10-18 1992-09-08 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5373095A (en) * 1985-10-18 1994-12-13 The Upjohn Company Steroid compounds
US5187299A (en) * 1985-10-18 1993-02-16 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4820714A (en) * 1986-05-02 1989-04-11 University Of Virginia Alumni Patents Foundation Use of phospholipase inhibitors in the treatment of Clostridium difficile diarrhea
US5001234A (en) * 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5124334A (en) * 1987-11-30 1992-06-23 Du Pont Merck Pharmaceutical Company Benzylalcohol phospholipase A2 inhibitors
US4948813A (en) * 1987-11-30 1990-08-14 E. I. Du Pont De Nemours And Company Benzylketone phospholipase A2 inhibitors
US5039706A (en) * 1987-11-30 1991-08-13 Du Pont Merck Pharmaceutical Company Antiinflammatory PLA2 inhibitors
US5218124A (en) * 1989-10-27 1993-06-08 American Home Products Corporation Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
US5086067A (en) * 1989-12-18 1992-02-04 G. D. Searle & Co. Ltb4 synthesis inhibitors
US5144045A (en) * 1990-11-13 1992-09-01 American Cyanamid Company Phosphocholine derivative inhibitors of phospholipase A2
US5298652A (en) * 1992-12-08 1994-03-29 Hoffmann-La Roche Inc. N-substituted glycines, inhibitors of phospholipase A2
HU213165B (en) * 1993-05-11 1997-02-28 Bot Process to prepare biopolymers with detoxicating activity
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
US5470882A (en) * 1994-06-02 1995-11-28 Smithkline Beecham Corp. Anti-inflammatory compounds
US5578639A (en) * 1994-07-01 1996-11-26 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
US5504073A (en) * 1994-07-01 1996-04-02 Warner-Lambert Company PLA2 inhibitors and their use for inhibition of intestinal cholesterol absorption
JPH08268916A (ja) * 1995-03-28 1996-10-15 Dai Ichi Seiyaku Co Ltd 微粒子性運搬体−薬物コンプレックス
JP3372408B2 (ja) * 1995-09-21 2003-02-04 第一製薬株式会社 微粒子性運搬体・薬物−コンプレックス
CA2262847C (en) * 1996-08-01 2007-06-05 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
JP2000516958A (ja) * 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US6290947B1 (en) * 1997-09-19 2001-09-18 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin-binding agents
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US6083497A (en) * 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6299868B1 (en) * 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2000010568A1 (en) * 1998-08-24 2000-03-02 Draheim Susan E Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase a¿2?
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
JP2002535288A (ja) * 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ.ア.エッセ. リポタンパク質複合体およびそれらを含む組成物
US7034006B2 (en) * 2000-01-10 2006-04-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
US6492550B2 (en) * 2000-02-18 2002-12-10 Bristol-Myers Squibb Company Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
US6908609B2 (en) * 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US6368842B1 (en) * 2000-12-15 2002-04-09 Pe Corporation (Ny) Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof
TWI314457B (cg-RX-API-DMAC7.html) * 2001-03-19 2009-09-11 Shionogi & Co
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
HUP0402577A3 (en) * 2001-12-03 2011-05-30 Wyeth Corp Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them
US20030225011A1 (en) * 2002-05-31 2003-12-04 Samuel David Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
US6565896B1 (en) * 2002-07-03 2003-05-20 Vitacost.Com, Inc. Cholesterol treatment formulation
WO2004060346A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition

Similar Documents

Publication Publication Date Title
JP2007538009A5 (cg-RX-API-DMAC7.html)
JP2004525179A (ja) ジペプチジルペプチダーゼiv阻害剤でのii型糖尿病の処置
JP4577985B2 (ja) ジフェニルエチレン化合物の新規な複素環類似体
CN109477993B (zh) β-羟基丁酸酯和丁二醇的中链脂肪酸酯和组合物及其使用方法
JP2020073468A (ja) 肝障害を処置するための1,3−ジフェニルプロパ−2−エン−1−オン誘導体の使用
RU2477275C1 (ru) Применение соединений формулы a-r-x или их фармацевтически приемлемых солей для получения фармацевтической композиции
RU2509076C2 (ru) Пролекарства нестероидных противовоспалительных средств (nsaia) c очень высокой скоростью проникновения через кожу и мембраны и новые медицинские применения указанных пролекарств
JP5752599B2 (ja) 酸化脂質化合物およびその使用
WO2010043592A1 (en) Lipase inhibitors for use for the treatment of obesity
JP2007536243A (ja) ホスホリパーゼ−a2阻害薬を用いた、高コレステロール血症、高トリグリセリド血症、心臓血管疾患の治療
CA2620274A1 (en) Methods for the treatment of senile dementia of the alzheimer's type
KR20130132836A (ko) 지질 화합물을 이용한 치료방법
JP2011502113A5 (cg-RX-API-DMAC7.html)
EP3592360A1 (fr) AceFaPC POUR LE TRAITEMENT DES MALADIES ACÉTYLCHOLINE DÉPENDANTES
CN1466465A (zh) 肥胖或脂肪肝的预防或治疗药物
WO2012109527A2 (en) Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
JP4511172B2 (ja) 肥満症および肥満症に随伴する疾患および/または二次疾患の治療および/または予防におけるトリフルオロアセチルアルキル置換されたフェニル誘導体、フェノール誘導体およびベンゾイル誘導体の使用
EP3493806A1 (en) New treatment for the non alcoholic steatohepatitis and fibrosis
WO2020074964A1 (en) Romatic compounds and pharmaceutical uses thereof
JP5997658B2 (ja) 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
CN103936710B (zh) N-取代的胡椒基戊二烯酰胺衍生物及其制备方法和应用
JP2015120703A (ja) 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
JP7418502B2 (ja) 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
KR101751533B1 (ko) 포스파티딜콜린 및 바이페닐-디메틸-디카르복실레이트를 포함하는 간 질환 예방 또는 치료용 조성물
WO1994023721A1 (fr) Nouvelle utilisation medicale d'un derive de dihydropyridine